hotspot -WSS

hotspot

author：leisure time 2025-10-02 20:59:40 - browse：6728

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： FDA approves potent Eli Lilly obesity drug, Zepbound

Wikipedia

WSS

Diversify hospital leadership teams to protect BIPOC patient health

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

Novo Nordisk obesity pill bests Wegovy in early trial

Former medical device CEO who sold dummy, plastic parts convicted of fraud

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

Removing probiotics from the NICU could threaten preemies' health

hotspot

hotspot

focus

Medicare details structure of new drug price negotiation program

The Sacklers, horror, and ‘The Fall of the House of Usher’

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

First medicine developed to treat MASH expected to be approved soon

Cancer drug shortages should be causing more outrage

Study: New antibiotic targets gonorrhea as well as last existing drug

Peter Hotez and the public health issue of online harassment

First medicine developed to treat MASH expected to be approved soon

After affirmative action ruling, medical educators look to 'holistic review'

Amylyx ALS drug failure raises questions and concerns

hotspot

UnitedHealth quietly bought dozens of outpatient centers

The new shift in health care is toward less care

Removing probiotics from the NICU could threaten preemies' health

Amylyx ALS drug fails large clinical trial

First medicine developed to treat MASH expected to be approved soon

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

focus

Wikipedia

focus

knowledge